HISTORY
We have successfully introduced innovative cell technologies to the Greater China region
Who We Are
Sinocell Biotechnology Co., Ltd. is a technology-driven enterprise specializing in biopharmaceutical and biotechnology research and development, as well as bioengineering innovation. The company focuses on fundamental research in stem cells, immune cells, and cell-derived exosomes, and is actively engaged in cell preparation, storage, quality control, and the development of cell-based therapeutics.
With a global perspective, Sinocell integrates top-tier talent and scientific resources, and actively strengthens collaborations with research institutes, clinical institutions, and standardization organizations both domestically and internationally. Committed to translating cutting-edge international advances in cellular medicine into practical and scalable clinical solutions, Sinocell places cellular medicine at its core to build a leading international model enterprise in advanced cell therapy, delivering hope for life and a promise of better health for people worldwide.
SCROLL
Our Vision
Honoring Life Through Technology
Our Mission
Let everyone benefit from cellular medicine
Our Values
Safety
Innovation
Authority
Three Platforms · Three Centers · Three Bases
Three Platforms
· Cell Public Research Platform
· Cell Technology Transfer and Translation Platform
· Academician & Expert Service Platform
Three Centers
· Cell Preparation Center
· Cell Quality Control & Testing Center
· Cell Storage Center
Three Bases
· Life Sciences Research Base
· Life Sciences Health Management Base
· Life Sciences Education & Exhibition Base
Development History
2003 - 2012
· 2003 — Prof. Kevin McElwee (UK) and Dr. Rolf Hoffman (Germany) first identified two novel stem cell types, NBDS and DPS, from hair follicles.
· 2012 — Following years of preclinical cell and animal studies confirming the efficacy and safety of stem cells, hair regeneration clinical trials were initiated in Germany.
2013 - 2017
• 2013 — Collaborated with Shiseido (Japan) to conduct multicenter hair regeneration ReHair clinical trials
• 2014 — Listed in Canada
• 2015 — Conducted stem cell skin rejuvenation ReBorn™ clinical trials in Germany
• 2015 — Conducted stem cell treatment for Achilles tendinitis ReBendon™ clinical trials in Canada
• 2017 — Invented the innovative cell injection device Cellinjector™
2018 - 2020
• 2018 — Became a major shareholder of a Canadian listed company and established Sinocell Biotechnology Co., Ltd. in Ningbo, China
In collaboration with a Singapore GMP consulting firm, a Hong Kong design team, and an EU GMP-certified cell preparation center, jointly developed the Sinocell Cell Preparation Center
• 2020 — A research project was selected for the 3315 Program. A Joint Stem Cell Regenerative Medicine Research Laboratory was established with the Zhejiang University College of Pharmaceutical Sciences. A Clinical Research and Translational Center was co-established with Ningbo First Hospital, and a Clinical Research Center for Allogeneic Stem Cell Therapy for Alzheimer’s Disease was co-established with Ningbo Kangning Hospital.
2021 - Now
• 2021 — Achieved ISO 9001:2015 Quality Management System certification through the British Standards Institution(BSI).
Recognized as Ningbo’s first “Academician Workstation,” “Enterprise Expert Workstation,” and “Life Sciences Science Education Base” led by Nobel Prize–winning scientists.
With a total investment of RMB 1 billion, selected the Putuo International Health Industry Park as the site to establish a landmark project focused on life sciences and health management, precision medicine, and wellness — the Sinocell (Zhoushan) Institute of Life Sciences and Technology.
Development History
2003 - 2012
· 2003 — Prof. Kevin McElwee (UK) and Dr. Rolf Hoffman (Germany) first identified two novel stem cell types, NBDS and DPS, from hair follicles.
· 2012 — Following years of preclinical cell and animal studies confirming the efficacy and safety of stem cells, hair regeneration clinical trials were initiated in Germany.
2013 - 2017
• 2013 — Collaborated with Shiseido (Japan) to conduct multicenter hair regeneration ReHair clinical trials
• 2014 — Listed in Canada
• 2015 — Conducted stem cell skin rejuvenation ReBorn™ clinical trials in Germany
• 2015 — Conducted stem cell treatment for Achilles tendinitis ReBendon™ clinical trials in Canada
• 2017 — Invented the innovative cell injection device Cellinjector™
2018 - 2020
• 2018 — Became a major shareholder of a Canadian listed company and established Sinocell Biotechnology Co., Ltd. in Ningbo, China
In collaboration with a Singapore GMP consulting firm, a Hong Kong design team, and an EU GMP-certified cell preparation center, jointly developed the Sinocell Cell Preparation Center
• 2020 — A research project was selected for the 3315 Program. A Joint Stem Cell Regenerative Medicine Research Laboratory was established with the Zhejiang University College of Pharmaceutical Sciences. A Clinical Research and Translational Center was co-established with Ningbo First Hospital, and a Clinical Research Center for Allogeneic Stem Cell Therapy for Alzheimer’s Disease was co-established with Ningbo Kangning Hospital.
2021 - Now
• 2021 — Achieved ISO 9001:2015 Quality Management System certification through the British Standards Institution(BSI).
Recognized as Ningbo’s first “Academician Workstation,” “Enterprise Expert Workstation,” and “Life Sciences Science Education Base” led by Nobel Prize–winning scientists.
With a total investment of RMB 1 billion, selected the Putuo International Health Industry Park as the site to establish a landmark project focused on life sciences and health management, precision medicine, and wellness — the Sinocell (Zhoushan) Institute of Life Sciences and Technology.